Beck Mack & Oliver LLC purchased a new stake in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 9,508 shares of the biopharmaceutical company’s stock, valued at approximately $1,750,000.
Several other large investors have also recently made changes to their positions in the stock. Quadrant Capital Group LLC raised its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares in the last quarter. FTB Advisors Inc. raised its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares in the last quarter. Duncker Streett & Co. Inc. purchased a new stake in shares of Shire PLC during the second quarter valued at about $111,000. West Oak Capital LLC purchased a new stake in shares of Shire PLC during the second quarter valued at about $126,000. Finally, NEXT Financial Group Inc purchased a new stake in shares of Shire PLC during the second quarter valued at about $126,000. Institutional investors and hedge funds own 24.26% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded down 1.17% during trading on Friday, hitting $188.82. The stock had a trading volume of 602,996 shares. Shire PLC has a one year low of $147.60 and a one year high of $231.32. The stock has a market capitalization of $56.24 billion, a price-to-earnings ratio of 39.24 and a beta of 1.16. The stock has a 50 day moving average price of $194.80 and a 200-day moving average price of $187.61.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. During the same quarter last year, the company earned $2.63 EPS. The company’s revenue was up 55.9% on a year-over-year basis. On average, equities research analysts predict that Shire PLC will post $12.92 earnings per share for the current year.
The business also recently disclosed a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
Several brokerages have recently issued reports on SHPG. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. HSBC lowered Shire PLC from a “buy” rating to a “hold” rating in a report on Monday, September 26th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a report on Monday, October 3rd. Piper Jaffray Cos. set a $201.00 target price on Shire PLC and gave the stock a “hold” rating in a report on Saturday, October 1st. Finally, Shore Capital restated a “buy” rating on shares of Shire PLC in a report on Saturday, August 13th. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. Shire PLC presently has a consensus rating of “Buy” and a consensus target price of $228.15.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.